Stereotaxis (NYSEAMERICAN:STXS) Coverage Initiated at Citizens Jmp

Equities researchers at Citizens Jmp began coverage on shares of Stereotaxis (NYSEAMERICAN:STXS) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The firm set a “market outperform” rating and a $4.00 price target on the stock. Citizens Jmp’s price objective would suggest a potential upside of 72.41% from the company’s previous close.

A number of other brokerages have also recently commented on STXS. Roth Capital restated a “buy” rating and issued a $4.00 price target on shares of Stereotaxis in a research report on Wednesday, November 12th. Citigroup assumed coverage on Stereotaxis in a research note on Tuesday. They set an “outperform” rating for the company. Finally, UBS Group set a $4.00 target price on shares of Stereotaxis in a report on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $4.00.

Stereotaxis Trading Down 2.5%

STXS opened at $2.32 on Tuesday. The company has a market cap of $216.50 million, a price-to-earnings ratio of -8.29 and a beta of 1.47. The company’s 50 day moving average is $2.64 and its 200 day moving average is $2.58. Stereotaxis has a 12-month low of $1.54 and a 12-month high of $3.59.

Insider Activity at Stereotaxis

In other Stereotaxis news, Director Paul J. Isaac acquired 20,000 shares of the business’s stock in a transaction dated Friday, November 14th. The shares were purchased at an average price of $2.24 per share, for a total transaction of $44,800.00. Following the completion of the purchase, the director directly owned 2,786,557 shares of the company’s stock, valued at $6,241,887.68. The trade was a 0.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 17.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stereotaxis

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Lagoda Investment Management L.P. lifted its stake in shares of Stereotaxis by 0.4% in the 3rd quarter. Lagoda Investment Management L.P. now owns 4,707,400 shares of the company’s stock valued at $14,640,000 after purchasing an additional 19,500 shares during the period. Vanguard Group Inc. increased its holdings in Stereotaxis by 4.2% in the third quarter. Vanguard Group Inc. now owns 3,441,091 shares of the company’s stock valued at $10,702,000 after buying an additional 138,482 shares in the last quarter. Essex Investment Management Co. LLC raised its position in shares of Stereotaxis by 3.5% in the third quarter. Essex Investment Management Co. LLC now owns 1,598,114 shares of the company’s stock worth $4,970,000 after acquiring an additional 53,358 shares during the period. Geode Capital Management LLC boosted its stake in shares of Stereotaxis by 0.9% during the 2nd quarter. Geode Capital Management LLC now owns 1,478,201 shares of the company’s stock worth $3,135,000 after acquiring an additional 13,891 shares in the last quarter. Finally, Warberg Asset Management LLC boosted its stake in shares of Stereotaxis by 260.1% during the 2nd quarter. Warberg Asset Management LLC now owns 1,201,500 shares of the company’s stock worth $2,547,000 after acquiring an additional 867,878 shares in the last quarter. Institutional investors and hedge funds own 45.35% of the company’s stock.

About Stereotaxis

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.